Floatz logo

Pyrotinib

Locally Advanced Rectal Cancer (LARC)

brenner baruchSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Locally Advanced Rectal Cancer (LARC) cohort.

Asset / SponsorPhaseRating
S-1
Tao Zhang
Phase 2CCC
rc48-adc
brenner baruch
Phase 2CCC
Tisleizumab
Tao Zhang
Phase 2CCC
Zanidatamab
Emory University
Phase 2CCC
Serplulimab
First Affiliated Hospital of Wenzhou Medical University
Phase 2CCC

Same molecule, other indications

Pyrotinib is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →